The FTC has issued a Second Request to Sanara MedTech and MiMedx, extending the antitrust review of their proposed merger.
SEC EDGAR, 2026-10-16: 8-K (Item 8.01) — "second request"
The FTC has issued a Second Request to Sanara MedTech and MiMedx, extending the antitrust review of their proposed merger.
Company: Sanara MedTech Inc. (SMTI) Filed: October 16, 2026, 8-K (Item 8.01) Phrase: "second request" — "On October 15, 2026, the Company and MiMedx each received a request for additional information and documentary materials (a “Second Request”) from the Federal Trade Commission (the “FTC”) in connection with the FTC’s review of the Merger." What the filing says: Sanara MedTech Inc. and MiMedx Group, Inc. each received a Second Request from the Federal Trade Commission on October 15, 2026, in connection with the FTC's antitrust review of their proposed merger. Under the merger agreement, a subsidiary of MiMedx will merge with and into Sanara, with Sanara surviving as a wholly-owned subsidiary of MiMedx. The Second Request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both parties have substantially complied with the request, unless the period is extended voluntarily or terminated earlier by the FTC. Two ways it goes: A. The FTC clears the merger after the parties substantially comply with the Second Request. B. The FTC sues to block the merger or the parties terminate the merger agreement. Next date: none named Watch: A public announcement or SEC filing indicating substantial compliance with the Second Request or a final decision by the FTC.